FDA Mulling Whether To Add Unannounced Inspections To Drug Safety Arsenal In China
This article was originally published in PharmAsia News
Executive Summary
SAN FRANCISCO - U.S. FDA's newly launched China office is still developing protocols for the country, and the agency is considering adding the use of unannounced inspections to its arsenal of tools crafted to improve product safety and quality